Global Hidradenitis Suppurativa Market Share Report 2024, Forecast To 2033

8 Mar, 2024

The hidradenitis suppurativa market rose from $1.06 billion in 2023 to $1.15 billion in 2024 (CAGR: 8.4%), propelled by increased awareness. Anticipated growth to $1.5 billion in 2028 (CAGR: 6.8%) is expected, driven by biologic therapies and telemedicine. Trends include advanced immunomodulation and patient-centric care.

Global Hidradenitis Suppurativa Market Key Driver

The hidradenitis suppurativa market is expanding due to the rising prevalence of skin diseases, with an estimated 106,110 new cases of skin cancer in the US in 2021. Increased awareness and research advancements drive the development of new products and services for the management of hidradenitis suppurativa.

Get A Free Sample Of The Global Hidradenitis Suppurativa Market Report

Global Hidradenitis Suppurativa Market Segments

The hidradenitis suppurativa market covered in this report is segmented –
1) Skin Condition:Folliculitis, Pimples, Boils, Deep-Acne
2) Product:Tablet, Intravenous (IV) Injection
3) Route Of Administration:Oral, Parenteral
4) Treatment:Medications, Surgery, Photodynamic Therapy (PDT), Laser Treatment, Other Treatments
5) End User:Hospital, Specialty Clinic, Homecare, Other End Users
By Geography: The countries covered in the hidradenitis suppurativa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. North America was the largest region in the hidradenitis suppurativa market in 2023. The regions covered in the hidradenitis suppurativa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Major Hidradenitis Suppurativa Industry Players

Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories; Eli Lilly and Co Ltd.; Amgen Inc.; Boehringer Ingelheim International GmbH; UCB S.A.; Incyte Corporation; Kyowa Kirin Co. Ltd.; Leo Pharma A/S; Almirall S.A.; Galapagos NV; Genentech Inc.; Tolmar Inc.; Alvotech Holdings S.A.; Aclaris Therapeutics Inc.; Kymera Therapeutics Inc.; Acelyrin Inc.; AnaptysBio Inc.; XBiotech Inc.; Arcutis Biotherapeutics Inc.; InflaRx N.V.; VYNE Therapeutics Inc.; Arena Pharmaceuticals Inc.; MoonLake Immunotherapeutics AG; Zynerba Pharmaceuticals Inc.

Get The Full Global Hidradenitis Suppurativa Market Report

Hidradenitis Suppurativa Market Overview

Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful lumps deep in the skin, usually on parts of the body where skin touches the skin, like the armpits, inner thighs, and groin area. These lumps frequently appear where skin contacts skin, such as the armpits, inner thighs, and groin.